edetic acid has been researched along with Androgen-Independent Prostatic Cancer in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Fütterer, JJ; Mehra, N; Nagarajah, J; Rovers, MM; Scheenen, TWJ; Smits, M; van Oort, IM; van Steenbergen, TRF | 1 |
| Baltzer, P; Berndl, F; D'Andrea, D; Fajkovic, H; Grubmüller, B; Grubmüller, KH; Hacker, M; Hartenbach, M; Kramer, G; Maj-Hes, A; Mitterhauser, M; Pfaff, S; Rasul, S; Shariat, SF; Wadsak, W | 1 |
| Bakshi, G; Banerjee, S; Basu, S; Joshi, A; Parghane, RV; Prabhash, K; Suman, S | 1 |
| Bal, C; Ballal, S; Damle, NA; Sahoo, RK; Seth, A; Tripathi, M; Yadav, MP | 1 |
| Kumar, R; Mittal, BR; Singh, H; Singh, SK; Vadi, SK | 1 |
| Baumann, M; Hölscher, T; Kotzerke, J; Krause, M; Löck, S; Lohaus, F; Troost, EGC; Wirth, M; Zöphel, K | 1 |
| Baum, RP; Klette, I; Kulkarni, HR; Mueller, D; Schottelius, M; Schuchardt, C; Singh, A; Wester, HJ; Wiessalla, S; Wirtz, M | 1 |
| Ahmadzadehfar, H; Essler, M; Gaertner, F; Schlenkhoff, CD; Schmidt, M | 1 |
| Bal, C; Ballal, S; Yadav, MP | 1 |
| Afshar-Oromieh, A; Aggarwal, R; Carroll, PR; Ehman, EC; Evans, MJ; Hope, TA; Ryan, CJ; Small, EJ; Truillet, C | 1 |
| Bode, A; Bögemann, M; Konnert, J; Rahbar, K; Stegger, L | 1 |
| Bode, A; Bögemann, M; Rahbar, K; Roll, W; Weckesser, M | 1 |
| Chen, Z; Cui, C; Du, J; Fan, Q; Hua, Z; Huang, Y; Jia, R; Li, TN; Shao, G; Sun, H; Tang, J; Wang, F; Yao, X; Zang, S | 1 |
13 other study(ies) available for edetic acid and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Topics: Aged; Bone and Bones; Bone Neoplasms; Cone-Beam Computed Tomography; Diffusion Magnetic Resonance Imaging; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Image-Guided Biopsy; Male; Middle Aged; Oligopeptides; Pilot Projects; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radiography, Interventional; Reproducibility of Results | 2020 |
Response assessment using [
Topics: Aged; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neoplasm Metastasis; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies | 2020 |
Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-direc
Topics: Biology; Edetic Acid; Humans; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2020 |
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Edetic Acid; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
68Ga-PSMA PET/CT Revealing Unusual Inguinal Canal and Distant Nodal Metastasis in a Case of Castration-Resistant Prostate Cancer.
Topics: Aged; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Inguinal Canal; Lymphatic Metastasis; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant | 2018 |
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Databases, Factual; Disease Progression; Dose Fractionation, Radiation; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oligopeptides; Positron-Emission Tomography; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radiosurgery; Retrospective Studies; Time Factors | 2019 |
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Topics: Aged; Antigens, Surface; Cohort Studies; Dipeptides; Disease-Free Survival; Edetic Acid; Erythrocyte Count; Gallium Isotopes; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Leukocyte Count; Lutetium; Male; Neoplasm Metastasis; Oligopeptides; Organometallic Compounds; Pain; Patient Selection; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiopharmaceuticals; Treatment Outcome | 2016 |
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Topics: Aged; Anemia; Antineoplastic Agents; Bone Marrow Diseases; Bone Neoplasms; Compassionate Use Trials; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Technetium Tc 99m Medronate | 2016 |
Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application.
Topics: Adult; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Male; Oligopeptides; Organometallic Compounds; Organophosphorus Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2016 |
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
Topics: Androgen Receptor Antagonists; Animals; Cell Line, Tumor; Drug Monitoring; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Mice; Mice, Nude; Middle Aged; Oligopeptides; Organometallic Compounds; Positron-Emission Tomography; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2017 |
Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy.
Topics: Aged; Carcinoma; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2016 |
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Topics: Aged; Bone Neoplasms; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2017 |
68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Topics: Aged; Aged, 80 and over; Asian People; Bone Neoplasms; China; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Risk Factors; Sensitivity and Specificity | 2017 |